Drug trial offers hope to avoid liver transplant for rare disease
NCT ID NCT00843440
Summary
This study tested whether the drug bevacizumab could help adults with a rare inherited bleeding disorder called HHT who developed severe, life-threatening liver complications. The goal was to see if this drug treatment could improve heart function and liver health, offering an alternative to a risky liver transplant. Researchers enrolled 25 patients to receive the drug and monitored their progress over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMORRHAGIC HEREDITARY TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospices Civils de Lyon
Lyon, France
Conditions
Explore the condition pages connected to this study.